ReviewJournal of ovarian research2026
Novel approaches to modulate CAR-T cell function by targeting the tumor microenvironment in ovarian cancer.
Review in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian cancer (OC) remains one of the most lethal gynecological malignancies despite advances in conventional therapeutic approaches. The dismal approximately 30% five-year survival rate for advanced disease highlight the urgent need for innovative treatment strategies. Chimeric antigen receptor T (CAR-T) cell therapy, having revolutionized treatment paradigms in hematological malignancies, faces significant challenges when applied to the complex immunosuppressive tumor microenvironment (TME) of ovarian cancer. This comprehensive review investigates critical research questions regarding the extent to which cellular and molecular components of the ovarian cancer TME inhibit CAR-T cell cytotoxic function, and the signaling patterns associated with reduced CAR-T cell infiltration or persistence in tumor masses. We systematically examine the multifaceted immunosuppressive mechanisms within the ovarian cancer TME and evaluate breakthrough strategies designed to overcome these barriers, including next-generation CAR engineering, combinatorial therapeutic approaches, and innovative TME-modulating technologies. The insights presented here provide a crucial roadmap for translating CAR-T therapy from promising concept to clinical reality in ovarian cancer treatment, potentially transforming outcomes for patients with this recalcitrant malignancy where innovative therapeutic options are urgently needed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.